ligelizumab (QGE 031) - Novartis
Xolair (omalizumab) - Roche, Novartis
UB-221 - United BioPharma
Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases. (PubMed, Allergy) - Aug 9, 2023 - "In this review, we discuss the current knowledge on the pathogenicity of autoreactive IgE in AbAID and their status as therapeutic targets. We also highlight unresolved issues including the need for assays that reproducibly quantify IgE AAbs, to validate their diagnostic and prognostic value, and to further study their pathophysiological contributions to AbAID." 
Journal • Review • Immunology
http://www.ncbi.nlm.nih.gov/pubmed/37555488
 
Carolin Steinert; Emek Kocaturk; Inge Kortekaas-Krohn; Jan Gutermuth; Jörg Scheffel; Laurent L Reber; Marcus Maurer; Nicolas Charles; Sabine Altrichter; Yi-Kui Xiang
 
Aug 9, 2023
 
Prev Next